Is Bryan Johnson's protocol legal to replicate?

The prescription medications (acarbose, metformin, testosterone, rapamycin) are legal with a valid prescription, even off-label. Peptides like BPC-157 exist in a gray zone: legal to prescribe through compounding pharmacies in some states, but not FDA-approved for human use. Supplements (NMN, various vitamins) are legal over-the-counter. No component of the published protocol involves scheduled controlled substances beyond testosterone (Schedule III).

How much of Bryan Johnson's protocol does insurance cover?

Roughly 10-15% of the pharmaceutical cost is potentially insurance-eligible, contingent on having qualifying diagnoses. The monitoring, peptides, NAD+ infusions, and off-label longevity prescriptions are overwhelmingly out-of-pocket. HSA/FSA accounts can cover some prescribed medications and labs.

What is the minimum effective version of this protocol?

The HealthRX Medical Team suggests that metformin or acarbose ($10-80/month), optimized sleep tracking ($0-30/month), quarterly basic metabolic labs ($200-400/year through insurance), and a structured exercise protocol capture the majority of current evidence-based longevity benefit at under $200/month total.

Why did Bryan Johnson stop rapamycin?

Johnson publicly disclosed in early 2024 that his epigenetic age clocks showed an unfavorable shift he attributed to rapamycin use. He discontinued the drug and shared his data openly. This aligns with ongoing uncertainty about optimal rapamycin dosing for longevity in humans, where the therapeutic window between immunosuppression and geroprotection remains undefined.

What Bryan Johnson's Longevity Protocol Would Cost Outside a Celebrity Context

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

Protocol status: Publicly confirmed and documented in detail on Johnson's Blueprint website and social channels
Reported annual spend: $2M+ (Johnson's own published figure, later revised downward to ~$500K as protocol simplified)
Insurance-coverable components: Acarbose, testosterone, metformin, standard labs
Cash-pay only components: Rapamycin (off-label), most peptides, NAD+ infusions, experimental biologics
Legal gray areas: BPC-157, GHK-Cu, hexarelin (not FDA-approved for human use)

The Public Record

Bryan Johnson, the tech entrepreneur who sold Braintree/Venmo to PayPal for $800 million, launched Project Blueprint in 2021 as an open-source attempt to reverse biological aging. His protocol has been confirmed directly through his published regimen lists, YouTube documentation, and public interviews with outlets including Bloomberg and Time magazine.

Johnson publishes his exact supplement stack, prescription medications, biomarker results, and protocol changes. In early 2024, he publicly confirmed discontinuing rapamycin after his biological age clocks showed a concerning shift, sharing the data transparently on social media.

This is not speculation. Johnson's protocol is the most thoroughly self-documented pharmaceutical longevity regimen in public existence.

Component-by-Component Cost Analysis for a Non-Celebrity Patient

Tier 1: Insurance-Eligible Prescriptions

Acarbose is an FDA-approved alpha-glucosidase inhibitor for type 2 diabetes. Johnson confirmed using it for longevity based on the ITP mouse lifespan data showing median lifespan extension. With a diabetes diagnosis, generic acarbose costs $15-40/month through insurance. Without that diagnosis, a cash-pay patient faces $30-80/month via GoodRx pricing. Most physicians will not prescribe it off-label for longevity without metabolic justification.

Testosterone optimization is confirmed in Johnson's protocol, with published blood levels. Standard TRT through an endocrinologist runs $30-150/month (generic cypionate) with insurance when hypogonadism is documented. Johnson's approach involves more frequent micro-dosing and monitoring than standard clinical practice, adding lab costs of $200-500 per quarter if run outside insurance panels.

Metformin, another confirmed component, costs $4-10/month generic. Off-label longevity prescriptions remain common through telehealth platforms at $50-150/month all-in with membership fees.

Tier 2: Legal but Cash-Pay Only

Rapamycin (sirolimus) was part of Johnson's protocol until early 2024. This mTOR inhibitor is FDA-approved for transplant rejection and certain cancers. Off-label longevity dosing (typically 3-6mg weekly, pulsed) requires a willing prescriber. The drug itself costs $2-5 per mg through compounding pharmacies, putting monthly cost at $50-150. The real barrier is physician willingness. A 2023 review in Aging Cell summarized human rapamycin trials, but no longevity indication exists. Most insurance will deny coverage without an approved diagnosis.

NAD+ precursors and infusions represent a significant cost tier. Johnson has confirmed using both NMN supplementation and NAD+ IV infusions. Pharmaceutical-grade NMN runs $50-150/month for oral dosing at 1g/day. NAD+ IV infusions cost $250-1,000 per session depending on geography, with protocols calling for weekly or biweekly sessions. Annual cost: $3,000-25,000. No insurance coverage exists. The clinical evidence for NAD+ repletion in humans remains preliminary, with most strong data from preclinical models.

Comprehensive biomarker panels are central to Blueprint. Johnson's published testing schedule includes full-body MRI ($1,500-3,000), DEXA scans ($150-300), continuous glucose monitoring ($150-350/month without diabetes diagnosis), epigenetic age testing ($300-500 per test), and quarterly blood panels running 80+ markers ($1,000-3,000 per draw when ordered outside insurance). Annual monitoring alone: $10,000-30,000 for a civilian replicating this frequency.

Tier 3: Regulatory Gray Zone

BPC-157 (Body Protection Compound) is a synthetic peptide Johnson has confirmed using. It is not FDA-approved for any human indication. The FDA issued a warning in 2023 regarding compounded peptides, and BPC-157 availability through compounding pharmacies has tightened. Where available, cost runs $100-300/month. Patients now increasingly source from research chemical suppliers, raising purity and legal concerns.

GHK-Cu and hexarelin occupy similar territory. Neither holds FDA approval for therapeutic use in humans. Compounding pharmacy access is inconsistent and state-dependent. Monthly costs range $150-400 per peptide when obtainable.

Johnson's confirmed peptide stack represents $500-1,500/month in compounds that exist in a regulatory limbo where legality depends on prescriber classification and state pharmacy board interpretation.

What Insurance Actually Covers

The HealthRX Medical Team reviewed Johnson's published protocol against standard U.S. commercial insurance formularies. The breakdown is stark:

| Category | Insurance path exists | Typical coverage barrier | |----------|---------------------|--------------------------| | Acarbose | Yes, with T2D diagnosis | Off-label denial without metabolic indication | | Testosterone | Yes, with documented hypogonadism | Prior authorization, lab thresholds | | Metformin | Yes, with prediabetes/T2D | Off-label denial for longevity | | Rapamycin | Technically yes (transplant/cancer) | No longevity indication; universal denial | | NAD+/NMN | No | Supplement or infusion; no drug coverage | | Peptides (BPC-157, GHK-Cu) | No | Not FDA-approved | | Advanced imaging | Partial | Screening MRI rarely covered without symptoms | | Epigenetic testing | No | Considered experimental |

A realistic annual estimate for a non-celebrity patient replicating the pharmaceutical core of Blueprint, excluding supplements, food, and equipment: $25,000-60,000 out-of-pocket, depending on peptide access and monitoring frequency.

The HealthRX Medical Team Take

Johnson's transparency is genuinely useful for the field. His published biological age reversal data and willingness to share protocol failures (like the rapamycin discontinuation) contribute real signal to longevity medicine.

But the access reality is this: the most evidence-backed components of his stack (metformin, acarbose, testosterone optimization, basic biomarker tracking) are accessible to middle-income patients at $200-500/month with a cooperative physician. These represent the interventions with the strongest human or near-human data.

The expensive tier (NAD+ infusions, advanced imaging cadence, peptide stacks) sits on substantially weaker clinical evidence. The CALERIE trial demonstrated that caloric restriction itself produces measurable biological age changes. Johnson's dietary protocol, olive oil regimen, and sleep optimization cost relatively little and carry the broadest evidence base.

Patients should resist the assumption that cost correlates with efficacy. A $300/month protocol built around sleep, metabolic health monitoring, and 2-3 evidence-supported pharmaceuticals captures most of what current longevity science can actually validate. The remaining $150,000+ in Johnson's protocol funds experimentation, not proven medicine.

Access Pathways for Key Components

For patients pursuing elements of this protocol:

Longevity-focused clinicians increasingly prescribe rapamycin, metformin, and acarbose off-label. Directories like the American Academy of Anti-Aging Medicine list practitioners, though quality varies enormously. Expect $300-600 for initial consultations.

Compounding pharmacies under 503B designation can legally produce rapamycin and certain peptides when prescribed. State-level restrictions apply. Patients in Texas, Florida, and California currently have broader compounding access than those in states with restrictive pharmacy boards.

Telehealth platforms have emerged specifically for longevity prescriptions. Monthly memberships ($99-299) typically include metformin and basic labs, with add-ons for rapamycin or NAD+ precursors.

Clinical trials offer free access to experimental longevity interventions. The TAME trial (Targeting Aging with Metformin) and various rapamycin studies actively recruit. ClinicalTrials.gov lists current enrollment options.

Frequently asked questions

›

References

Harrison DE, et al. "Acarbose improves health and lifespan in aging HET3 mice." Aging Cell. 2014. https://pubmed.ncbi.nlm.nih.gov/24245565/
Mannick JB, et al. "Targeting the biology of aging with mTOR inhibitors." Aging Cell. 2023. https://pubmed.ncbi.nlm.nih.gov/36856148/
Yoshino J, et al. "NAD+ intermediates: The biology and therapeutic potential." Cell Metabolism. 2018. https://pubmed.ncbi.nlm.nih.gov/29514064/
Kraus WE, et al. "2 years of calorie restriction and cardiometabolic risk (CALERIE)." Lancet Diabetes Endocrinol. 2022. https://pubmed.ncbi.nlm.nih.gov/35443107/
Barzilai N, et al. "Metformin as a tool to target aging." Cell Metabolism. 2016. https://pubmed.ncbi.nlm.nih.gov/31802682/
Selvarani R, et al. "Effect of rapamycin on aging and age-related diseases." GeroScience. 2021. https://pubmed.ncbi.nlm.nih.gov/34058823/
Lu AT, et al. "DNA methylation GrimAge version 2." Aging. 2023. https://pubmed.ncbi.nlm.nih.gov/37943209/
Bloomberg News. "How to Be 18 Years Old Again for Only $2 Million a Year." Jan 2023. https://www.bloomberg.com/news/features/2023-01-25/anti-aging-techniques-high-tech-billionaire-bryan-johnson-spends-2-million-a-year
Time Magazine. "Bryan Johnson's Quest to Not Die." 2024. https://time.com/6955597/bryan-johnson-dont-die/
FDA. "Bulk Drug Substances Used in Compounding." 2023. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-federal-food-drug-and-cosmetic-act